Abstract-Ionizing radiation exposure to the general U.S. population nearly doubled between 1980 and 2006, due almost entirely to the significant increase in the number of radiologic and nuclear medicine procedures performed. Significant changes in the types of procedures and radionuclides used in nuclear medicine, as well as in detection technology, have led to notable changes over time in absorbed doses to specific organs. This study is the first to estimate per-procedure organ doses to nuclear medicine patients and trends in doses over five decades. Weighted average organ doses per examination to 14 organs of interest were calculated for 17 examination types over 10 5-y time periods as the product of the percentage of use of each radiopharmaceutical in those diagnostic procedures based on comprehensive literature review, the administered activity, and ICRP dose coefficients; doses per radiopharmaceutical were also provided for each organ, procedure, and time period. The weighted doses to adult nuclear medicine patients from cardiac procedures increased to all organs of interest between 1960 and 2010 except for the urinary bladder wall. From high radiation doses for most other procedures in the 1960s, with up to 0.7 Gy in the specific case of radioiodinated thyroid scans, organ-absorbed doses generally decreased from 1960 to 1990. In contrast, during the 1990s and 2000s, the weighted doses were gradually increased for some procedures, such as brain and skeleton scans. The increasing number of nuclear medicine procedures, specifically cardiac scans and changes in weighted doses, underscore the need to monitor exposure levels and radiationrelated disease risks in nuclear medicine patients. Health Phys. 113(6): 474-518; 2017 
INTRODUCTION
NUCLEAR MEDICINE (NM) techniques developed in the second half of the 20th century, including planar imaging, Single Photon Emission Computed Tomography (SPECT), and Positron Emission Tomography (PET), have become very sophisticated and have been extensively involved in diagnostic testing. NM procedures rely on the intravenous, oral, or inhaled administration of radiopharmaceuticals selected for their fixation on given tissues of interest. A surge of new radiopharmaceuticals has resulted in an increasing use of NM procedures over this time period.
The number of NM procedures performed increased from 23.5 to 37 million worldwide between 1980 -1984 and 1997 -2007 (UNSCEAR 1988 NCRP 2009 ) and 7 to 18.6 million in the United States between 1980 -1982 (NCRP 1989 . Thus, by 2006, half of the NM procedures in the world were performed in the United States. The estimated annual per capita effective dose from NM studies performed in the United States increased by a factor 5.5, from 0.14 mSv in 1980 -1982 (NCRP 1987 ) to 0.77 mSv in 2006 (NCRP 2009 According to data of the NCRP (2009), in 2006, cardiac studies accounted for 57% of the total number of diagnostic NM procedures and were responsible for 85.2% of the collective effective doses from NM procedures. Bone scan studies accounted for 20% of diagnostic NM procedures and 9.3% of collective effective doses from NM, and gastrointestinal tract studies accounted for 7% of NM procedures and 1.6% of collective effective doses from NM. On the other hand, therapeutic NM procedures represented a small percentage of the total number of NM procedures. Iodine-131 treatments for hyperthyroidism and thyroid cancer accounted for more than 90% of the total therapeutic NM procedures (NCRP 2009; ICRP, 2004) .
Important technical developments over the past decades that have impacted diagnostic NM procedures and led to changes with time in absorbed doses to specific organs included the development of the first molybdenum-99/technetium-99 m generator, the first synthesis of of PET/CT scanner. Furthermore, the increasing number of diagnostic NM procedures observed in the U.S. over the past decades represents a general radiation safety concern and underlines the need to monitor exposure levels.
The purpose of this study is to characterize temporal trends in organ doses received by U.S. adult patients from nuclear medicine procedures assuming some typical attributes of the patient; e.g., body size and kinetic behavior of the radiopharmaceutical. Accordingly, the authors accounted for not only the dosimetric properties of each radionuclide but also its relative frequency of use in each time period. These dosimetric data not only give a valuable historical overview of changes in radiopharmaceuticals and their relative usage in nuclear medicine but also represent a valuable resource for epidemiologic studies that include diagnostic medical radiation.
MATERIALS AND METHODS
The usual way of estimating organ-absorbed dose to a patient from a nuclear medicine procedure is by the product of the administered activity and the relevant dose coefficient. However, because different patients undergoing the same examination type, even within the same year, may have been administered different isotopes or different radiopharmaceuticals, the authors also derived a weighted average organ absorbed dose per examination, which is a weighted average dose for each type of diagnostic NM examination in the United States within the years 1960 to 2010, with weighting factors equal to the fractional usage of radiopharmaceuticals for that examination type that were available at the time. The weighted dose as defined here has not been received by any individual patient but, rather, is representative of the weighted average dose for a type of examination considering that more than one radiopharmaceutical, each with different dosimetric properties, may have been used for the same examination type in a given time period. Hereafter, this artificial quantity simply is referred to as the weighted dose. The weighted dose would have the greatest use in epidemiology or in other types of descriptive analyses that do not, or cannot, account for specific isotopes or radiopharmaceuticals.
Historical information about NM diagnostic procedures performed, relative usage of radiopharmaceuticals, chemical form, and typical administered activity of each radionuclide in each 5-y time period was based on the authors' previous comprehensive literature survey and interviews with experienced nuclear medicine practitioners, summarized in Table 2 of Drozdovitch et al. (2015) . Accordingly, the weighted dose to male and female adult patients undergoing nuclear medicine procedures within a defined period was based on the Reference Man and Woman definitions from ICRP Publication 23 (ICRP 1975) 
where D T,k,l is the absorbed dose (mGy) to the organ or tissue, weighted by the procedure type k within year l, due to radiopharmaceutical m. p k,l,m is the proportion of the k procedures conducted in year l with radiopharmaceutical m. A k, l,m is the administered activity (MBq) for the specified k, l, and m, and d T,m is the dose coefficient (mGy MBq −1 ) expressed in absorbed dose per unit administered activity for the specific T and m.
Dose coefficients were obtained from ICRP publications 53, 80 and 106 (ICRP 1987 (ICRP , 1998 (ICRP , 2008 . The source of information about the ICRP dose coefficients used for the radiopharmaceuticals used in specific time periods is based on the authors' earlier survey (Drozdovitch et al. 2014 (Drozdovitch et al. , 2015 as shown in Table 1 .
The authors also provided the organ doses per radiopharmaceutical for the administered activity specified in Drozdovitch et al. (2015) , as they could be useful for retrospective dosimetry or epidemiology studies when the administered radiopharmaceutical is known. The absorbed organ dose to male and female adult patients undergoing nuclear medicine procedures, per radiopharmaceutical and within a defined period, was defined as follows:
where D T,l is the absorbed dose (mGy) to the organ or tissue within year l. A l is the administered activity (MBq) and d T is the dose coefficient (mGy MBq ) expressed in absorbed dose per unit administered activity for the specific organ or tissue T.
In the current study, the 17 most regularly performed types of diagnostic NM procedures were considered, including blood volume, bone marrow scan, brain scan and brain blood flow, cardiac procedures, GI bleeding and Meckel's scan, hepatobiliary scan, iron metabolism, liver scan, lung ventilation, lung perfusion, pancreas scan, kidney scan, bone scan, thyroid scan, thyroid uptake, and tumor localization (Drozdovitch et al. 2015) .
Estimates of the weighted doses to 14 organs of interest of adult nuclear medicine patients are described in Tables  2-15 for thyroid, red bone marrow, lung, breast, stomach wall, liver, colon wall, kidney, urinary bladder wall, ovary, testis, brain, esophagus, and heart wall. The selection of these 14 organs was primarily based on the BEIRVII report (NRC 2006) along with consideration of outcomes repeatedly evaluated in the epidemiologic risk assessment literature. Absorbed doses per radiopharmaceutical to these 14 organs of interest are also described in Tables 2-15 . No further distinction was made for paired organs (e.g, kidney) or partial organ irradiation. In this study, the whole organ was considered as the target organ for the dose calculations.
A few assumptions were made regarding the dose coefficients from ICRP publications:
• Dose coefficients for 99m Tc-pertechnetate were used without modification for thyroid blocking for thyroid scan, thyroid uptake, and cardiac procedures based on the assumption that no thyroid blocking agents were used; • Dose coefficients for 99m Tc-pertechnetate were also used for brain scan without modification for thyroid blocking, assuming again no blocking agent was used;
• Dose coefficients for 99m Tc-pertechnetate were assumed with and without a blocking agent for brain blood flow since there was no consensus in the literature on whether blocking agents were used; • Dose coefficients for 131 I-sodium iodide and 123 I-sodium iodide were used assuming 25% thyroid uptake for thyroid scan and thyroid uptake procedures; and • Dose coefficients of 59 Fe-citrate with oral administration were used for iron metabolism.
All dose estimates presented in Tables 2 through 15 are presented with a maximum of two significant digits (and sometimes less) to reflect the limited state of knowledge.
RESULTS
This paper provides estimates of weighted doses, as well as absorbed doses per radiopharmaceutical, to 14 different organs in 5-y intervals from 1960 to 2010 for all nuclear medicine adult patients in the U.S. from 17 diagnostic Table 2 . Estimates of the weighted doses and radiopharmaceutical-specific absorbed doses (mGy) to the breast in 1960-2010 from nuclear medicine examinations.
Decade and absorbed dose to breast (mGy)
Type of examination 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 Blood volume 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 Brain scan Continued next page procedures using 49 specific radiopharmaceuticals. The organ absorbed doses derived for each examination and time period use typical body sizes and biokinetic characteristics as specified for the Reference Man by the International Commission on Radiation Protection (ICRP, 1975) . Derived weighted doses and absorbed doses per radiopharmaceutical are provided in Tables 2-15 for breast, colon wall, kidney, liver, lung, ovary, red bone marrow, stomach wall, testis, thyroid, urinary bladder wall, brain, and heart wall for the 50-y time period of interest.
Radiopharmaceutical

Dose variations over time and procedures
As expected, the numerous changes in procedures and radionuclides that occurred between 1960 and 2010 led to changes with time in the weighted doses to specific organs both over time for a given procedure and over procedures within each time-period. For example, radiation doses to kidney from brain scans varied up to 102-fold between 1960-1964 and 1970-1974, and radiation dose to liver during 1960-1964 varied by up to 70,000 times greater from bone marrow scan compared to thyroid uptake. The largest dose variation over time was observed for thyroid scans; the weighted thyroid doses from thyroid scans varied by up to 530 mGy between 1960-1964 and 2005-2010 . The large variability observed highlights that historical studies of exposure cannot assume a single dose for each procedure type without additional information related to the specific radiopharmaceutical used and the associated administered activity.
Breast
Prior to 1970, the highest exposures to breast from a given procedure were due to tumor localization (61 mGy), followed by pancreas scan (9.6 mGy) and brain blood flow (8.1 mGy), as summarized in Table 2 . Over the past 50 y, the weighted breast doses due to these three types of diagnostic NM procedures were reduced by factors of 13, 2.5, and 5.8, respectively. The weighted breast doses from cardiac procedures increased from 0.39 mGy in the early years (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) to 3.5 mGy. Other examination types that resulted in weighted breast doses above 1 mGy (for the entire observed time period) were bone marrow scan, brain scan, and GI bleeding and Meckel's scan.
Colon wall
Prior to 1970, the highest exposures to the colon wall were due to tumor localization (57 mGy), followed by hepatobiliary scan (47 mGy) and pancreas scan (16 mGy), as summarized in Table 3 . Between 1960 and 2010, weighted colon wall doses due to these three types of NM procedures were notably reduced by factors of 7.6, 3.4, and 2.9, respectively.
Exposures to the colon wall from cardiac procedures increased markedly over time, from 1.5 mGy in the early years (1965) (1966) (1967) (1968) (1969) (1970) to 20 mGy in the last time-period (2005-2010) , as can be observed in Fig. 1 . The weighted 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 Tumor localization Tc-DTPA aerosol administered activity into the patient's lungs of 27.75 MBq (1,300 MBq in the nebulizer). Table 3 . Estimates of the weighted doses and radiopharmaceutical-specific absorbed doses (mGy) to the colon wall in 1960-2010 from nuclear medicine examinations.
Decade and absorbed dose to colon wall (mGy)
Type of examination Radiopharmaceutical 1960 Radiopharmaceutical -1964 Radiopharmaceutical 1965 Radiopharmaceutical -1969 Radiopharmaceutical 1970 Radiopharmaceutical -1974 Radiopharmaceutical 1975 Radiopharmaceutical -1979 Radiopharmaceutical 1980 Radiopharmaceutical -1984 Radiopharmaceutical 1985 Radiopharmaceutical -1989 Radiopharmaceutical 1990 Radiopharmaceutical -1994 Radiopharmaceutical 1995 Radiopharmaceutical -1999 Radiopharmaceutical 2000 Radiopharmaceutical -2004 Radiopharmaceutical 2005 Radiopharmaceutical -2010 Blood volume 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 Brain scan Continued next page colon wall doses also increased over the five decades for brain scan, liver scan, and GI bleeding and Meckel's scan, by a factor of 3.3%, 79%, and 36%, respectively. From the early years, doses from kidney scan and thyroid scans increased from 0.57 and 0.09 mGy, respectively, to 1.2 and 3.5 mGy in the most recent period. Other NM examinations, such as bone marrow scan, brain blood flow, iron metabolism, and bone scan, resulted in weighted colon wall doses above 1 mGy over time.
Kidney
The NM examinations that delivered the highest doses to the kidney in the earlier period (1960) (1961) (1962) (1963) (1964) were brain scan (411 mGy), tumor localization (98 mGy), and kidney scan (43 mGy), as summarized in Table 4 . Between 1960 and 2010, weighted kidney doses due to these three types of NM procedures were substantially reduced by factors of 41, 4.9, and 17, respectively. During the 50-y period, cardiac procedures and bone scan all delivered increasing weighted kidney doses, up to, respectively, 28 and 6.8 mGy in the last time period (2005) (2006) (2007) (2008) (2009) (2010) . Weighted kidney doses greater than 1 mGy were absorbed by the kidney from bone marrow scan, brain blood flow, GI bleeding and Meckel's scan, liver scan, and pancreas scan.
Liver
The NM examinations that delivered the highest doses to the liver in the earlier period (1960) (1961) (1962) (1963) (1964) were bone marrow scan (455 mGy), brain scan (109 mGy), and tumor localization (80 mGy), as summarized in Table 5 . Between 1960 and 2010, weighted liver doses due to these three types of NM procedures were reduced by factors of 12, 18, and 5.4, respectively. Cardiac procedures led to increasing doses over time, from 0.67 mGy in the early years (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) to 10 mGy. Except for blood volume and iron metabolism, and thyroid scan/thyroid uptake, the remaining examinations delivered weighted liver doses predominately greater than 1 mGy.
Lung
Prior to 1970, the highest exposures to lung were due to tumor localization procedures (167 mGy), followed by lung perfusion (26 mGy) and brain blood flow (22 mGy), as summarized in Table 6 . Over the past 50 y, weighted lung doses due to these three types of nuclear medicine procedures were reduced by factors of 16, 2.2, and 1.6, respectively. Cardiac procedures led to increasing doses over time, from 0.72 mGy in the early years (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) to 6.9 mGy during 2005-2010. Other examination types that resulted in weighted lung doses above 1 mGy between 1960 and 2010 were bone marrow scan, brain scan, GI bleeding and Meckel's scan, pancreas scan, and bone scan.
Ovary
Prior to 1970, the highest exposures to ovary were due to tumor localization (54 mGy), followed by pancreas scan 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 Tumor localization Table 4 . Estimates of the weighted doses and radiopharmaceutical-specific absorbed doses (mGy) to the kidney in 1960-2010 from nuclear medicine examinations.
Decade and absorbed dose to kidney (mGy)
Type of examination Radiopharmaceutical 1960 Radiopharmaceutical -1964 Radiopharmaceutical 1965 Radiopharmaceutical -1969 Radiopharmaceutical 1970 Radiopharmaceutical -1974 Radiopharmaceutical 1975 Radiopharmaceutical -1979 Radiopharmaceutical 1980 Radiopharmaceutical -1984 Radiopharmaceutical 1985 Radiopharmaceutical -1989 Radiopharmaceutical 1990 Radiopharmaceutical -1994 Radiopharmaceutical 1995 Radiopharmaceutical -1999 Radiopharmaceutical 2000 Radiopharmaceutical -2004 Radiopharmaceutical 2005 Radiopharmaceutical -2010 Blood volume 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 99m Tc-glucoheptonate Tc-DTPA aerosol administered activity into the patient's lungs of 27.75 MBq (1,300 MBq in the nebulizer).
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Decade and absorbed dose to liver (mGy)
Type of examination 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 Blood volume www.health-physics.com 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 99m Tc-SC Tc-DTPA aerosol administered activity into the patient's lungs of 27.75 MBq (1,300 MBq in the nebulizer). Table 6 . Estimates of the weighted doses and radiopharmaceutical-specific absorbed doses (mGy) to the lung in 1960-2010 from nuclear medicine examinations.
Radiopharmaceutical
Decade and absorbed dose to lung (mGy)
Type of examination 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 Blood volume www.health-physics.com
Copyright © 2017 Health Physics Society. Unauthorized reproduction of this article is prohibited. 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 99m Tc-glucoheptonate Tc-DTPA aerosol administered activity into the patient's lungs of 27.75 MBq (1,300 MBq in the nebulizer). Table 7 . Estimates of the weighted doses and radiopharmaceutical-specific absorbed doses (mGy) to the ovary in 1960-2010 from nuclear medicine examinations.
Decade and absorbed dose to ovary (mGy)
Type of examination 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 Blood volume 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 99m Tc-SC Tc-DTPA aerosol administered activity into the patient's lungs of 27.75 MBq (1,300 MBq in the nebulizer). Table 8 . Estimates of the weighted doses and radiopharmaceutical-specific absorbed doses (mGy) to the red bone marrow in 1960-2010 from nuclear medicine examinations.
Decade and absorbed dose to red bone marrow (mGy)
Radiopharmaceutical
Copyright © 2017 Health Physics Society. Unauthorized reproduction of this article is prohibited. 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 99m Tc-glucoheptonate 
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Meckel's scan Tc-DTPA aerosol administered activity into the patient's lungs of 27.75 MBq (1,300 MBq in the nebulizer). Table 9 . Estimates of the weighted doses and radiopharmaceutical-specific absorbed doses (mGy) to the stomach wall in 1960-2010 from nuclear medicine examinations.
Decade and absorbed dose to stomach wall (mGy)
Type of examination 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 Blood volume 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 99m Tc-SC Tc-DTPA aerosol administered activity into the patient's lungs of 27.75 MBq (1,300 MBq in the nebulizer). Table 10 . Estimates of the weighted doses and radiopharmaceutical-specific absorbed doses (mGy) to the testis in 1960-2010 from nuclear medicine examinations.
Radiopharmaceutical
Decade and absorbed dose to testis (mGy)
Type of examination 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 Blood volume 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 99m Tc-glucoheptonate Tc-DTPA aerosol administered activity into the patient's lungs of 27.75 MBq (1,300 MBq in the nebulizer). Table 11 . Estimates of the weighted doses and radiopharmaceutical-specific absorbed doses (mGy) to the thyroid in 1960-2010 from nuclear medicine examinations.
Radiopharmaceutical
Decade and absorbed dose to thyroid (mGy)
Type of examination 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 Blood volume 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 99m Tc-SC Tc-DTPA aerosol administered activity into the patient's lungs of 27.75 MBq (1,300 MBq in the nebulizer). Table 12 . Estimates of the weighted doses and radiopharmaceutical-specific absorbed doses (mGy) to the urinary bladder wall in 1960-2010 from nuclear medicine examinations.
Decade and absorbed dose to urinary bladder wall (mGy)
Type of examination 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 Blood volume Brain blood flow w. www.health-physics.com
Copyright © 2017 Health Physics Society. Unauthorized reproduction of this article is prohibited. 1960-1964 1965-1969 1970-1974 1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2010 99m Tc-glucoheptonate Meckel's scan Meckel's scan Meckel's scan (20 mGy) and brain blood flow (7.3 mGy), as summarized in Table 7 . Over the past 50 y, weighted ovary doses due to these three types of NM procedures were reduced, respectively, by factors of 7.0, 3.4, and 3.0. Cardiac procedures and kidney scans also led to substantially increased exposures over time, from 2.0 and 0.41 mGy, respectively, in the early years (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) to 9.1 mGy and 1.9 mGy (Fig. 2) . The weighted ovary doses increased slightly over the five decades for three other examinations: 43% for brain scan, 26% for GI bleeding and Meckel's scan, and 18% for bone scan. Finally, exposures to the ovary remained greater than 1 mGy from hepatobiliary scan and bone marrow scans between 1960 and 2010.
Red bone marrow
The NM examinations that delivered the highest doses to the red bone marrow prior to 1960 were bone marrow scan (105 mGy), tumor localization (73 mGy), and both liver and pancreas scan (14 mGy), as summarized in Table 8 . Between 1960 and 2010, weighted red bone marrow doses due to these four types of NM procedures were reduced by factors of 17, 10, 8.2 and 2.7, respectively. Three NM examinations led to slightly increased exposures over time, by 24% for cardiac procedures (with a peak of 10 mGy between 1975 and 1985), 27% for bone scan, and 22% for GI bleeding and Meckel's scan. Other NM examinations, such as brain blood flow and brain scan, resulted in weighted red bone marrow doses above 1 mGy during the study period.
Stomach wall
The NM examinations that delivered the highest doses to the stomach wall prior to 1960 were tumor localization (59 mGy), pancreas scan (17 mGy), and bone marrow scan (12 mGy), as summarized in Table 9 . Between 1960 and 2010, weighted stomach wall doses due to these three types of NM procedures were reduced by factors of 8.7, 3.5, and 3.3, respectively. From the early years, doses from cardiac procedures scan and thyroid scans increased from 0.67 and 0.85 mGy, respectively, to 7.0 and 2.8 mGy in the most recent period. The weighted stomach wall doses increased slightly over the five decades for GI bleeding and Meckel's scan by about 29%. Other NM examinations, such as brain blood flow, brain scan, liver scan, and bone scan, resulted in weighted stomach wall doses above 1 mGy on average over time.
Testis
Prior to 1970, the highest exposures to testis were due to tumor localization (51 mGy), followed by pancreas scan (17 mGy) and brain blood flow (6.8 mGy), as summarized in Table 10 . In 50 y, weighted testis doses due to these three types of NM procedures were reduced by factors of 8.6, 3.7, and 4.5, respectively. Exposures from cardiac procedures increased by a factor of 4.5 over the five decades. The weighted testis doses increased slightly between 1960 and 2010 from GI bleeding and Meckel's scan and brain scan by 24% and 19%, respectively. From 0.26 mGy in the early years, kidney scan delivered an increased amount of radiation, with 1.3 mGy in the most recent period. Finally, exposures to testis remained greater than 1 mGy from bone scans between 1960 and 2010. scan and pancreas scan increased by 22% from 2.7 mGy and by 23% and 13 mGy, respectively, over five decades (Table 13) .
Esophagus
Similar to the situation for the brain, no dose coefficients were published for the esophagus in ICRP Publication 53 (ICRP 1987) . Consequently, the weighted esophagus doses could only be calculated in the current study for radiopharmaceuticals whose dose coefficients were updated in ICRP Publications 80 (ICRP 1998 ) or 106 (ICRP 2008 : GI bleeding and Meckel's scan and pancreas scan. From 15 mGy prior to 1970, the exposure to the esophagus from pancreas scan was reduced over five decades by a factor 2.9. In contrast, an increase was observed for GI bleeding and Meckel's scan; from 4.5 mGy prior to 1970, the weighted esophagus doses increased by 22% over five decades (Table 14) .
Heart wall
Similar to the situation for the brain and esophagus, no dose coefficients were published for the heart wall in ICRP Publication 53 (ICRP 1987) . Consequently, the weighted heart wall doses could be calculated only for radiopharmaceuticals with dose coefficients from publications 80 (ICRP 1998) or 106 (ICRP 2008) of the ICRP: blood volume, cardiac procedures, GI bleeding and Meckel's scan, iron metabolism, pancreas scan, and tumor localization. The NM examinations that delivered the highest doses to the heart wall prior to 1970 were tumor localization (211 mGy), GI bleeding and Meckel's scan (17 mGy), and pancreas scan (17 mGy), as summarized in Table 15 . Between 1960 and 2010, the weighted heart wall doses from tumor localization were reduced by a factor of 6.3. In contrast, GI bleeding and Meckel's scan and pancreas scan led to weighted heart wall doses that increased by 21% and 65%, respectively. Exposure to heart wall from cardiac procedures also increased over the five decades, from 0.67 mGy in the early years to 11 mGy in the last period, as can be observed in Fig. 5 . Iron metabolism studies resulted in weighted heart wall doses of 1.2 mGy between 1960 and 2010.
DISCUSSION AND CONCLUSION
To the authors' knowledge, this is the first study to provide a comprehensive summary of weighted doses for NM patients or for individual radiopharmaceuticals for 14 organs of interest, 17 NM procedures, and 49 radiopharmaceuticals between 1960 and 2010 in the United States. A significant decrease of absorbed doses to organs was observed in the 1960s through the 1980s for most procedures and for most organs of interest due to replacement by radiopharmaceuticals that delivered lower doses; in particular, those labeled with 99m
Tc. These trends are demonstrated in Tables 2 to  15 . In contrast, with the advent of PET imaging procedures and the use of 18 F-FDG in recent decades, patient absorbed doses increased with cardiac procedures and GI bleeding and Meckel's scans.
Observed dose increases
The phenomenon of increasing dose in later years was mainly due to increases in administered activities of some 99m Tc-labeled radiopharmaceuticals, respectively, As an example, the weighted doses averaged over all organs of interest from GI bleeding and Meckel's scan increased by 25% over the five decades. An absorbed dose decrease was observed between the mid-1970s and early 1990s, when Tc-RBC (administered activity of 740 MBq) was used less and replaced by 99m Tc-pertechnetate (administered activity of 185 MBq).
Another phenomenon was observed for tumor localization procedures: Although the global evolution over the five decades was an absorbed dose decrease, due to a large decrease in the first two decades (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) , the weighted doses increased again for several organs (e.g., urinary bladder wall, heart wall, lung, and kidney) by factors of 7.6, 4.4, 1.5, and 1.5, respectively, as can be observed in Fig. 6 .
Cardiac procedures
The weighted doses from cardiac procedures to all organs of interest except for urinary bladder wall (and brain, absorbed dose not available) increased over the five decades, by a factor 8.6 ± 4.4 (Fig. 7) . The absorbed doses to urinary bladder wall from cardiac procedures varied compared to other organs of interest, decreased by a factor of 3.7 between the 1960s and mid-1970s, and then increased by a factor of 1.6 in the mid-1970s. In the early years, 99m Tcpyrophosphate was the primary radiopharmaceutical in use (1965) (1966) (1967) (1968) (1969) but was replaced 10 y after mostly by 201 Tl-chloride (1975 Tl-chloride ( -1979 . The highest absorbed doses, averaged over all organs, were observed between the mid1970s and early 1990s when 201 Tl-chloride was the most widely used radiopharmaceutical for cardiac procedures. The weighted doses then decreased for most organs, except for breast, colon, and the urinary bladder wall. In the most recent time-periods, the primary radiopharmaceutical in use was 99m Tc-sestamibi (rapid 1-d protocol), which accounted for 55% of the use in the late 2000s, followed by 99m Tc-tetrofosmin (20% in the late 2000s). In both cases, very high activities were administered after the early 1990s (1.11 GBq). Absorbed doses received from cardiac procedures in 2005-2010 were still high, ranging from 3.5 to 28 mGy, depending on the organ of interest.
Limitations
The dose estimates presented here have limitations and uncertainties that should be understood. Primarily, and as noted earlier, organ-specific weighted doses are average values weighted by the relative usage of the radiopharmaceuticals used within a time-period. Accordingly, the trends presented here should be interpreted in that light as they are not necessarily representative of a specific exposure, radionuclide or radiopharmaceutical. However, organ doses per radiopharmaceutical, without weighting factors, are provided in Tables 2-15 for those instances when the dose specific to a radiopharmaceutical is needed.
A second limitation is that the radiopharmaceuticals based on the survey by Drozdovitch et al. (2015) may not completely reflect all practices and usage in the United States. Some of the radiopharmaceuticals that may have been used were possibly not reported in that study, or the reported data might not be representative of all medical facilities. These limitations contribute to the overall uncertainty. Moreover, it is likely that the administered activities to various current radiopharmaceuticals may have varied since 2010. The weighted doses and absorbed doses per radiopharmaceutical from the last 5-y period (2005) (2006) (2007) (2008) (2009) (2010) should therefore be used with additional caution for any study after 2010.
Another source of uncertainty is related to the values of administered activities that were used to calculate the absorbed doses. Although activity is actually administered according to the age and weight of the patient, in this study, typical administered activities were derived from an extensive literature review (Drozdovitch et al. 2015) . Variations in the amount of administered activity for individual patients can lead to differences in absorbed doses that are not necessarily reflected in the findings of this study. In addition, there are uncertainties associated with organ dose estimates that reflect uncertainty in dose coefficients, which are calculated from reference anthropomorphic phantoms without gender specificity and, hence, cannot be representative of all patient anatomies but only of average-sized ones. The authors used a consistent methodology for all calculations, however.
The dose coefficients used in this study were provided by the ICRP publications 53 (ICRP 1987 ), 80 (ICRP 1998 , ) calculations were performed on stylized anthropomorphic phantoms, known not to be fully realistic and leading, on some occasions, to over-or underestimation of dose. With the development and publication of more realistic reference phantoms, the male and female ICRP Publication 110 adult reference computational models (ICRP 2009), representing average-sized reference male, female, and pediatric patients from ICRP Publication 89 (ICRP 2002), a few specific S values have been published recently (Lamart et al. 2016; Villoing et al. 2017 ) for a few radionuclides. Future efforts to update dose coefficients in the coming years will provide an opportunity to possibly improve the organ doses that have been derived here. In contrast to the first two types of uncertainty, which are inherent to the variations among patients and clinical centers and, hence, probably cannot be reduced, this last source of uncertainty may be reduced with improved dose coefficients.
Most important here is the reminder that the doses presented in the main text (called weighted doses) are weighted estimates, even though they assume attributes and dosimetric parameters for typical adult patients. It is clear that these doses do not apply to any identified individual. All estimates have inherent uncertainties reflecting the various limitations of the data and methodology discussed above.
In conclusion, this study summarized trends in the weighted doses to 14 different organs based on 17 types of diagnostic NM procedures commonly performed in the United States between 1960 and 2010. Absorbed doses per radiopharmaceutical are also available for the same organs of interest, procedures, and time periods. The dose estimates presented here may need to be updated in the next decade with several improvements (e.g., the use of more realistic computational phantoms for deriving dose factors) to account for any further changes in radiopharmaceutical usage proportions, as well as to account for any new medical procedures involving radionuclides that are introduced. Doses could also be calculated for brain and heart wall for more nuclear medicine procedures. The data presented here are, for the present, the most complete available for understanding the temporal changes in dose from specific types of diagnostic nuclear medicine examinations. These data represent a valuable resource for epidemiologic studies that include medical radiation either as a primary or secondary source of exposure.
